C-Met As a Prognostic Marker in Gastric Cancer: a Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 14

PMID 24223894

Citations 49

Authors

Shan Yu

Yiyi Yu

Naiqing Zhao

Jianlan Cui

Wei Li

Tianshu Liu

Affiliations

Soon will be listed here.

Abstract

Background: c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis.

Methods: We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity.

Results: 15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage.

Conclusions: Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis.

Citing Articles

siRNA-based strategies to combat drug resistance in gastric cancer.

Khaleel A, Alshahrani M, Rizaev J, Malathi H, Devi S, Pramanik A Med Oncol. 2024; 41(11):293.

PMID: 39428440 DOI: 10.1007/s12032-024-02528-w.

Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review.

Wei W, Hong Y, Deng Y, Wang G, Qiu J, Pan F World J Gastrointest Oncol. 2024; 16(8):3397-3409.

PMID: 39171189 PMC: 11334049. DOI: 10.4251/wjgo.v16.i8.3397.

Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer.

Wang L, Zhang W, Qiu Y, Wang F World J Gastrointest Oncol. 2024; 16(6):2781-2792.

PMID: 38994139 PMC: 11236228. DOI: 10.4251/wjgo.v16.i6.2781.

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.

Yuan P, Xue X, Qiu T, Ying J Ther Adv Med Oncol. 2024; 16:17588359231221910.

PMID: 38249331 PMC: 10798113. DOI: 10.1177/17588359231221910.

Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics.

Megid T, Farooq A, Wang X, Elimova E Cancers (Basel). 2023; 15(20).

PMID: 37894443 PMC: 10605200. DOI: 10.3390/cancers15205075.

References

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

Han S, Lee H, Lee J, Kim W, Nam H, Kim H . Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg. 2005; 242(5):676-83. PMC: 1409863. DOI: 10.1097/01.sla.0000186171.85804.fe. View

Lee H, Kim M, Lee H, Jung E, Yang H, Lee B . MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012; 107(2):325-33. PMC: 3394975. DOI: 10.1038/bjc.2012.237. View

Lennerz J, Kwak E, Ackerman A, Michael M, Fox S, Bergethon K . MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011; 29(36):4803-10. PMC: 3255989. DOI: 10.1200/JCO.2011.35.4928. View

Huang T, Wang J, Lin S, Lian S, Hsieh J . Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol. 2001; 40(5):638-43. DOI: 10.1080/028418601750444204. View

Lee J, Seo J, Jun H, Ki C, Park S, Park Y . Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011; 25(6):1517-24. DOI: 10.3892/or.2011.1219. View

Yi S, Tsao M . Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia. 2000; 2(3):226-34. PMC: 1507572. DOI: 10.1038/sj.neo.7900080. View

Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D . Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 2004; 95(10):803-8. PMC: 11158965. DOI: 10.1111/j.1349-7006.2004.tb02185.x. View

Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, Trautwein C . p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002; 47(1):114-21. DOI: 10.1023/a:1013275706401. View

10.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

11.

Catenacci D, Cervantes G, Yala S, Nelson E, El-Hashani E, Kanteti R . RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011; 12(1):9-46. PMC: 3149873. DOI: 10.4161/cbt.12.1.15747. View

12.

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

13.

Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K . Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 2011; 130(12):2912-21. DOI: 10.1002/ijc.26330. View

14.

Ajani J . Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw. 2008; 6(9):813-4. View

15.

Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992; 189(1):227-32. DOI: 10.1016/0006-291x(92)91548-5. View

16.

Li Y, Chen C, He Y, Cai S, Yang D, He W . Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012; 106(3):304-10. DOI: 10.1002/jso.23008. View

17.

Kim J, Sun C, Mailey B, Prendergast C, Artinyan A, Bhatia S . Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol. 2009; 21(1):152-60. DOI: 10.1093/annonc/mdp290. View

18.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

19.

Tang Z, Zhao M, Ji J, Yang G, Hu F, He J . Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep. 2004; 11(2):333-9. View

20.

Wu C, Li A, Chi C, Chung W, Liu T, Lui W . Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep. 1998; 5(4):817-22. DOI: 10.3892/or.5.4.817. View